Payment overview · 2025
General Payments
$113.72
7 reported records · 2 companies
Healthcare provider profile · identity verified
James Akins, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SCOTT DEPOT, WV · NPI 1285638684
Verified facts
What the public records show
CMS Open Payments records show James Akins, M.D. received $113.72 in general payments during 2025 across 7 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 87.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Xifaxan.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $99.83 | 87.8% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.89 | 12.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.72 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99.83 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 61 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 358 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 108 |
| Gabapentin | Gabapentin | 282 | 55 |
| Clonazepam | Clonazepam | 233 | 41 |
| Lisinopril | Lisinopril | 230 | 64 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 216 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 54 |
| Alprazolam | Alprazolam | 207 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 193 | 52 |
| Furosemide | Furosemide | 189 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 52 |
| Lorazepam | Lorazepam | 164 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 20 |
| Metformin Hcl | Metformin Hcl | 147 | 46 |
| Losartan Potassium | Losartan Potassium | 143 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 39 |
| Levofloxacin | Levofloxacin | 141 | 87 |
| Prednisone | Prednisone | 134 | 96 |
| Omeprazole | Omeprazole | 125 | 40 |
| Ozempic | Semaglutide | 120 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 37 |
| Cefdinir | Cefdinir | 116 | 87 |
| Potassium Chloride | Potassium Chloride | 112 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 26 |
| Valsartan | Valsartan | 101 | 29 |
| Montelukast Sodium | Montelukast Sodium | 100 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 23 |
| Celecoxib | Celecoxib | 97 | 29 |
| Dexamethasone | Dexamethasone | 95 | 74 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 95 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 29 |
| Diazepam | Diazepam | 85 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 22 |
| Fluconazole | Fluconazole | 84 | 33 |
| Allopurinol | Allopurinol | 80 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 23 |
| Donepezil Hcl | Donepezil Hcl | 76 | 24 |
| Meloxicam | Meloxicam | 72 | 33 |
| Bupropion Xl | Bupropion Hcl | 69 | 15 |
| Ezetimibe | Ezetimibe | 69 | 22 |
| Nabumetone | Nabumetone | 67 | 15 |
| Eliquis | Apixaban | 61 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 15 |
| Simvastatin | Simvastatin | 57 | 17 |
| Trazodone Hcl | Trazodone Hcl | 57 | 12 |
| Azithromycin | Azithromycin | 56 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 15 |
| Tramadol Hcl | Tramadol Hcl | 52 | 19 |
| Carvedilol | Carvedilol | 51 | 14 |
| Mounjaro | Tirzepatide | 49 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 11 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 45 | 11 |
| Ondansetron Odt | Ondansetron | 45 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Dutasteride | Dutasteride | 39 | 13 |
| Famotidine | Famotidine | 39 | 13 |
| Atenolol | Atenolol | 37 | suppressed |
| Glipizide | Glipizide | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 13 |
| Fentanyl | Fentanyl | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | 20 |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 17 |
| Clarithromycin | Clarithromycin | 27 | 23 |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 11 |
| Estradiol | Estradiol | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 11 |
| Etodolac | Etodolac | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 17 |
| Metronidazole | Metronidazole | 18 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Itraconazole | Itraconazole | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pentasa | Mesalamine | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.72 · 7 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ELIQUIS, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error